Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28905527 | 0.81 | ADRA1D (0.33) | MEN1KMT2AADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL7988951 | 0.64 | HDAC6 (0.40) | AURKAKDRKDM4C | |
| SCHEMBL28606812 | 0.62 | CDK5 (0.33) | KDM4C | |
| SCHEMBL3631373 | 0.61 | — | — | |
| SCHEMBL17694181 | 0.61 | KDM4C (0.40) | AURKAKDRKDM4C | |
| SCHEMBL23954205 | 0.61 | MEN1 (0.32) | MEN1KMT2AADRA1DADRA1AADRA1B | |
| SCHEMBL2968451 | 0.60 | AURKA (0.31) | AURKAKDR | |
| SCHEMBL31187621 | 0.60 | CHRNB4 (0.42) | MEN1KMT2AADRA1DADRA1AADRA1B | |
| SCHEMBL19296202 | 0.60 | CDK5 (0.32) | AURKAKDRKDM4C | |
| SCHEMBL20117864 | 0.59 | AURKA (0.30) | AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170250363-A1 | LIGHT-EMITTING LAYER SUITABLE FOR BRIGHT LUMINESCENCE | CYNORA GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-7491745-B2 | Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2007-02-15 | — | — | US | disclosed |
| US-7144912-B2 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | GEMIN X BIOTECHNOLOGIES INC. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20050049292-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | GEMIN X PHARMACEUTICALS CANADA INC. (CA) | 2005-03-03 | — | — | US | disclosed |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | GEMIN X BIOTECHNOLOGIES INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049292-A1 | Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression | PYCR1, ZC3HAV1, POLI | MEN1 1046/4885KMT2A 2215/4885ADRA1D 4862/4885 |
| US-20040014987-A1 | Pyrrole-Type compounds, compositions, and methods for treating cancer or viral diseases | POLI, PYCR1, ZC3HAV1 | MEN1 1724/4885KMT2A 2024/4885ADRA1D 4860/4885 |
| US-20070037856-A1 | e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide | POLI, PCNA, ELL | MEN1 2200/4885KMT2A 1863/4885ADRA1D 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.